Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection
Congenital cytomegalovirus (cCMV) infection is a major cause of childhood deafness. Most cCMV infections are not diagnosed without newborn screening, resulting in missed opportunities for directed care. To estimate the cost-effectiveness of universal and targeted newborn cCMV screening programs comp...
Saved in:
Published in | JAMA pediatrics Vol. 170; no. 12; p. 1173 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.12.2016
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Congenital cytomegalovirus (cCMV) infection is a major cause of childhood deafness. Most cCMV infections are not diagnosed without newborn screening, resulting in missed opportunities for directed care.
To estimate the cost-effectiveness of universal and targeted newborn cCMV screening programs compared with no cCMV screening.
Models were constructed using rates and outcomes from prospective cohort studies of newborn cCMV screening in US postpartum care and early hearing programs. Costs of laboratory testing, treatment, and hearing loss were drawn from Medicaid data and published estimates. The benefits of cCMV screening were assumed to come from antiviral therapy for affected newborns to reduce hearing loss and from earlier identification of hearing loss with postnatal onset. Analyses were performed from July 2014 to March 2016.
Models compared universal or targeted cCMV screening of newborns with a failed hearing screen, with standard care for cCMV infection.
The incremental costs of identifying 1 cCMV infection, identifying 1 case of cCMV-related hearing loss, and preventing 1 cochlear implant; the incremental reduction in cases of severe to profound hearing loss; and the differences in costs per infant screened by universal or targeted strategies under different assumptions about the effectiveness of antiviral treatment.
Among all infants born in the United States, identification of 1 case of cCMV infection by universal screening was estimated to cost $2000 to $10 000; by targeted screening, $566 to $2832. The cost of identifying 1 case of hearing loss due to cCMV was as little as $27 460 by universal screening or $975 by targeted screening. Assuming a modest benefit of antiviral treatment, screening programs were estimated to reduce severe to profound hearing loss by 4.2% to 13% and result in direct costs of $10.86 per newborn screened. However, savings of up to $37.97 per newborn screened were estimated when costs related to functionality were included.
Newborn screening for cCMV infection appears to be cost-effective under a wide range of assumptions. Universal screening offers larger net savings and the greatest opportunity to provide directed care. Targeted screening also appears to be cost-effective and requires testing for fewer newborns. These findings suggest that implementation of newborn cCMV screening programs is warranted. |
---|---|
AbstractList | Congenital cytomegalovirus (cCMV) infection is a major cause of childhood deafness. Most cCMV infections are not diagnosed without newborn screening, resulting in missed opportunities for directed care.
To estimate the cost-effectiveness of universal and targeted newborn cCMV screening programs compared with no cCMV screening.
Models were constructed using rates and outcomes from prospective cohort studies of newborn cCMV screening in US postpartum care and early hearing programs. Costs of laboratory testing, treatment, and hearing loss were drawn from Medicaid data and published estimates. The benefits of cCMV screening were assumed to come from antiviral therapy for affected newborns to reduce hearing loss and from earlier identification of hearing loss with postnatal onset. Analyses were performed from July 2014 to March 2016.
Models compared universal or targeted cCMV screening of newborns with a failed hearing screen, with standard care for cCMV infection.
The incremental costs of identifying 1 cCMV infection, identifying 1 case of cCMV-related hearing loss, and preventing 1 cochlear implant; the incremental reduction in cases of severe to profound hearing loss; and the differences in costs per infant screened by universal or targeted strategies under different assumptions about the effectiveness of antiviral treatment.
Among all infants born in the United States, identification of 1 case of cCMV infection by universal screening was estimated to cost $2000 to $10 000; by targeted screening, $566 to $2832. The cost of identifying 1 case of hearing loss due to cCMV was as little as $27 460 by universal screening or $975 by targeted screening. Assuming a modest benefit of antiviral treatment, screening programs were estimated to reduce severe to profound hearing loss by 4.2% to 13% and result in direct costs of $10.86 per newborn screened. However, savings of up to $37.97 per newborn screened were estimated when costs related to functionality were included.
Newborn screening for cCMV infection appears to be cost-effective under a wide range of assumptions. Universal screening offers larger net savings and the greatest opportunity to provide directed care. Targeted screening also appears to be cost-effective and requires testing for fewer newborns. These findings suggest that implementation of newborn cCMV screening programs is warranted. |
Author | Goshen, Oran Fowler, Karen Dionne, Francois Kozak, Fred K Park, Albert H Goldfarb, David M Gantt, Soren Boppana, Suresh B |
Author_xml | – sequence: 1 givenname: Soren surname: Gantt fullname: Gantt, Soren organization: Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada3BC Children's Hospital, Vancouver, British Columbia, Canada – sequence: 2 givenname: Francois surname: Dionne fullname: Dionne, Francois organization: Centre for Clinical Epidemiology and Evaluation, Vancouver, British Columbia, Canada – sequence: 3 givenname: Fred K surname: Kozak fullname: Kozak, Fred K organization: BC Children's Hospital, Vancouver, British Columbia, Canada5Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada – sequence: 4 givenname: Oran surname: Goshen fullname: Goshen, Oran organization: Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada – sequence: 5 givenname: David M surname: Goldfarb fullname: Goldfarb, David M organization: Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada3BC Children's Hospital, Vancouver, British Columbia, Canada – sequence: 6 givenname: Albert H surname: Park fullname: Park, Albert H organization: Department of Surgery, University of Utah, Salt Lake City – sequence: 7 givenname: Suresh B surname: Boppana fullname: Boppana, Suresh B organization: Department of Pediatrics, University of Alabama, Birmingham8Department of Microbiology, University of Alabama, Birmingham – sequence: 8 givenname: Karen surname: Fowler fullname: Fowler, Karen organization: Department of Pediatrics, University of Alabama, Birmingham9Department of Epidemiology, University of Alabama, Birmingham |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27723885$$D View this record in MEDLINE/PubMed |
BookMark | eNo1T19LwzAcDKK4OfcVJF-gM7-kbZpHKf4ZDH1wex5J-kvpWJORdJN9e-vUe7jjjuPg7si1Dx4JocAWwBg87nSvD9h0eoidTQvOoLzQFZlyKKus5AATMk9px0ZUjOVC3pIJl5KLqiqmpK1DGjJ0Du3QndBjSjQ4uvGjiUnvqfYNXevY4oANfccvE6KnnzYi-s631IVI6-Db0Q1juz4PocdW78Opi8dEl_4yHPw9uXF6n3D-pzOyeXle12_Z6uN1WT-tMl0ADJkttLQm10pagLx0QuncGCkVGKzAFY47rpGhAlCFdQIlCGN_ElRCVIrPyMPv7uFoemy2h9j1Op63_4_5Nz-nX5A |
CitedBy_id | crossref_primary_10_1128_JCM_01951_19 crossref_primary_10_1097_MOO_0000000000000925 crossref_primary_10_1002_lary_27032 crossref_primary_10_1001_jamanetworkopen_2020_23949 crossref_primary_10_1136_archdischild_2017_314404 crossref_primary_10_1016_j_jogc_2021_05_015 crossref_primary_10_1016_j_amjoto_2017_06_002 crossref_primary_10_1016_j_jogc_2021_05_014 crossref_primary_10_1093_infdis_jiz373 crossref_primary_10_1111_dmcn_13582 crossref_primary_10_1007_s40136_020_00291_w crossref_primary_10_1097_DBP_0000000000000843 crossref_primary_10_1007_s00404_017_4380_2 crossref_primary_10_1891_NN_2023_0069 crossref_primary_10_3390_jcm10215056 crossref_primary_10_3389_fped_2022_988039 crossref_primary_10_1111_jpc_16239 crossref_primary_10_1016_j_ijporl_2021_110818 crossref_primary_10_1016_j_semperi_2021_151393 crossref_primary_10_3389_fepid_2023_1270374 crossref_primary_10_1371_journal_pone_0227143 crossref_primary_10_1080_03007995_2023_2222583 crossref_primary_10_1016_S0163_4453_17_30197_4 crossref_primary_10_3390_ijns6040080 crossref_primary_10_1016_j_ijporl_2020_110594 crossref_primary_10_1002_lary_30108 crossref_primary_10_1016_j_jcjq_2020_06_002 crossref_primary_10_1053_j_semperi_2018_02_002 crossref_primary_10_3390_microorganisms9081749 crossref_primary_10_1177_03000605211062448 crossref_primary_10_1136_archdischild_2017_312805 crossref_primary_10_1016_j_jpeds_2018_02_064 crossref_primary_10_1111_jpc_14428 crossref_primary_10_1186_s13584_023_00566_9 crossref_primary_10_3138_jammi_2019_08_21 crossref_primary_10_1016_j_jcv_2022_105186 crossref_primary_10_3389_fpubh_2024_1359663 crossref_primary_10_3390_ijns4020020 crossref_primary_10_1097_INF_0000000000002144 crossref_primary_10_1159_000512525 crossref_primary_10_1111_apa_13959 crossref_primary_10_1002_uog_26226 crossref_primary_10_1128_jcm_00313_23 crossref_primary_10_1016_j_jcv_2023_105527 crossref_primary_10_1016_j_jviromet_2019_113759 crossref_primary_10_1016_j_clinmicnews_2023_05_001 crossref_primary_10_1097_AUD_0000000000000682 crossref_primary_10_3390_ijns9020030 crossref_primary_10_1016_j_antiviral_2021_105083 crossref_primary_10_1097_AUD_0000000000001411 crossref_primary_10_5385_nm_2019_26_2_96 crossref_primary_10_1016_j_jogn_2020_02_005 crossref_primary_10_1016_j_ijporl_2020_110055 crossref_primary_10_1136_bmjopen_2023_071997 crossref_primary_10_1007_s40274_016_3476_4 crossref_primary_10_1016_j_ejpn_2022_01_019 crossref_primary_10_1093_infdis_jiz601 crossref_primary_10_1038_jp_2017_41 crossref_primary_10_1016_S1473_3099_17_30143_3 crossref_primary_10_1093_infdis_jiz446 crossref_primary_10_1038_s41372_019_0364_3 crossref_primary_10_1002_rmv_1938 crossref_primary_10_1038_s41372_020_00801_0 crossref_primary_10_1016_j_jcv_2020_104337 crossref_primary_10_1136_archdischild_2016_311859 crossref_primary_10_3310_PYTK6591 crossref_primary_10_1002_lary_26819 crossref_primary_10_3389_fped_2020_00013 crossref_primary_10_5694_mja2_51406 crossref_primary_10_1016_j_ijporl_2023_111555 crossref_primary_10_1007_s40136_020_00296_5 crossref_primary_10_1371_journal_pone_0185635 crossref_primary_10_3390_ijns9030040 crossref_primary_10_1093_ofid_ofae311 crossref_primary_10_1136_bmjph_2023_000838 crossref_primary_10_3390_ijns9030044 crossref_primary_10_1128_spectrum_04041_22 crossref_primary_10_18553_jmcp_2021_27_2_157 crossref_primary_10_3390_ijns9020017 crossref_primary_10_1055_s_0043_1768036 crossref_primary_10_1186_s12962_019_0189_0 crossref_primary_10_3390_jcm13123379 crossref_primary_10_1002_jmv_28391 crossref_primary_10_1016_j_clinthera_2021_12_007 crossref_primary_10_1002_rmv_1925 crossref_primary_10_1097_INF_0000000000002808 crossref_primary_10_1038_nrdp_2016_94 crossref_primary_10_1177_0194599820957288 crossref_primary_10_1136_archdischild_2018_316010 crossref_primary_10_1136_archdischild_2022_324699 crossref_primary_10_1038_s41591_024_02873_3 crossref_primary_10_1542_neo_22_9_e606 crossref_primary_10_47102_annals_acadmedsg_2021459 crossref_primary_10_1097_INF_0000000000001763 crossref_primary_10_1186_s12879_019_4296_5 crossref_primary_10_3389_fped_2022_909646 crossref_primary_10_1093_cid_ciz413 crossref_primary_10_1097_MD_0000000000019419 crossref_primary_10_1016_j_anpede_2022_11_004 crossref_primary_10_1093_cid_ciz415 crossref_primary_10_3389_fgene_2022_867354 crossref_primary_10_1044_leader_AEA_22012017_18 crossref_primary_10_1177_0009922817724400 crossref_primary_10_3390_ijns8040065 crossref_primary_10_1016_j_anpedi_2022_09_003 crossref_primary_10_3390_ijns6040094 crossref_primary_10_1186_s12887_022_03384_1 crossref_primary_10_1177_0194599818758247 crossref_primary_10_1016_j_eclinm_2021_100872 crossref_primary_10_1080_14787210_2017_1303377 crossref_primary_10_1016_j_ijporl_2023_111450 crossref_primary_10_1007_s40746_022_00261_y crossref_primary_10_1002_rmv_2072 crossref_primary_10_14639_0392_100X_2020 crossref_primary_10_1111_apa_14212 crossref_primary_10_1097_QCO_0000000000000874 crossref_primary_10_1016_j_jcv_2018_05_001 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1001/jamapediatrics.2016.2016 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2168-6211 |
ExternalDocumentID | 27723885 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GroupedDBID | 0R~ 4.4 53G AAWTL ABJNI ACGFS ACIWK ACPRK ADBBV AENEX AFOSN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EJD EMOBN EX3 H13 HF~ NPM OB4 OBH OHH OVD PONUX PQQKQ RAJ SV3 TEORI WOW |
ID | FETCH-LOGICAL-a511t-c5a7cb4a97c1146f39a4bb7791be81f5f2f2ae0e91195cf3e713bcae0ee933892 |
IngestDate | Sat Sep 28 08:36:42 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-a511t-c5a7cb4a97c1146f39a4bb7791be81f5f2f2ae0e91195cf3e713bcae0ee933892 |
OpenAccessLink | https://jamanetwork.com/journals/jamapediatrics/articlepdf/2557388/poi160056.pdf |
PMID | 27723885 |
ParticipantIDs | pubmed_primary_27723885 |
PublicationCentury | 2000 |
PublicationDate | 2016-12-01 |
PublicationDateYYYYMMDD | 2016-12-01 |
PublicationDate_xml | – month: 12 year: 2016 text: 2016-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | JAMA pediatrics |
PublicationTitleAlternate | JAMA Pediatr |
PublicationYear | 2016 |
References | 29359492 - Acta Paediatr. 2018 May;107(5):906 27723888 - JAMA Pediatr. 2016 Dec 1;170(12):1142-1144 |
References_xml | |
SSID | ssj0000800437 |
Score | 2.5831711 |
Snippet | Congenital cytomegalovirus (cCMV) infection is a major cause of childhood deafness. Most cCMV infections are not diagnosed without newborn screening, resulting... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1173 |
SubjectTerms | Cost Savings Cost-Benefit Analysis Cytomegalovirus Infections - congenital Cytomegalovirus Infections - diagnosis Cytomegalovirus Infections - economics Early Diagnosis Hearing Loss - economics Hearing Loss - prevention & control Hearing Loss - virology Humans Infant Infant, Newborn Medicaid - economics Neonatal Screening - economics Parents - psychology Personal Satisfaction Prospective Studies United States |
Title | Cost-effectiveness of Universal and Targeted Newborn Screening for Congenital Cytomegalovirus Infection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27723885 |
Volume | 170 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELUWkCouFYVCC7TygRtytXY-nBzR8qVKwIFF4oZsr10tiPWKDZXgL_CnGcd2ki4UtVysyNZa2czz5Nl5M4PQTqpgE9AvJUlFmZIUOAcRRamI--ArKR05EDm1xWl-fJH-vMwue72njmrpvpI_1OOrcSXvsSr0gV1dlOx_WLaZFDrgGuwLLVgY2n-y8cDOKuIVGdFpAfcLWouQBGBYS72BVoI7A3u71eykNlFAObAuuMpVDtkdPFT2VsMbw_4e393PwHV4ndbkDwILTnp3Gut7NIT8CAxUu_Nz2wku2x87GU3kx8qO2y9H9lHc-AG4teao9cjOQrTI2V2AbTiRoHlH3aFrz8VoXpCcBS8a3awvEBLxxDpek1JfzuSFO2_LCLR_zMnx8rrp_gQMM72tzcy4q6Pm6wC9PTqXaDsOLaAFXjhneRoOfq4DsU4THrRgMW_Va3fl0kuHmea2KjVlGa6gj2Gvgfc8cD6hnp6sog8nQU2xhn69xA-2Bjf4wYAfHPGDA35wgx8M-MEtfvAcfnCDn8_o4vBgODgmofAGEcC_K6IywZWE1cuVC1o3SSlSKTkvqdQFNZlhhgnd16XLF6hMojlNpHI9ukyAAbN1tDixE_0FYZ2OeCYFz5gogC8xQZnIDEyXjFTfCPUVbfhHdDX12VWu4sPb_OvIFlpuYbeNlgwsZ_0NuGElv9dWewboO2hP |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost-effectiveness+of+Universal+and+Targeted+Newborn+Screening+for+Congenital+Cytomegalovirus+Infection&rft.jtitle=JAMA+pediatrics&rft.au=Gantt%2C+Soren&rft.au=Dionne%2C+Francois&rft.au=Kozak%2C+Fred+K&rft.au=Goshen%2C+Oran&rft.date=2016-12-01&rft.eissn=2168-6211&rft.volume=170&rft.issue=12&rft.spage=1173&rft_id=info:doi/10.1001%2Fjamapediatrics.2016.2016&rft_id=info%3Apmid%2F27723885&rft_id=info%3Apmid%2F27723885&rft.externalDocID=27723885 |